Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRG-110 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Single Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Multiple Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Multiple Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Name | Type | Description |
|---|---|---|
| MRG-110 | DRUG | Single ascending doses of MRG-110 |
| Placebo | DRUG | Single doses of placebo |
Key Inclusion Criteria: * Normal healthy volunteers. * Females must be of non-childbearing potential. * If engaged in sexual relations with a female of child-bearing potential, males must be surgically sterile or must be willing to use a highly effective method of contraception throughout their stu...
MRG-110 is an investigational small molecule developed by CASI Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease indications for MRG-110 have not been disclosed.
MRG-110 is being developed by CASI Pharmaceuticals, Inc., which trades under the ticker CASI. The company sponsored the Phase 1 study of MRG-110 conducted in the United States.
MRG-110 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study enrolled 42 healthy volunteers and evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics.
MRG-110 has been evaluated in one completed Phase 1 trial, NCT03603431, titled Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers. The trial enrolled 42 participants in the United States and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial NCT03603431 assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRG-110 after intradermal injection in healthy volunteers. It enrolled 42 participants aged 19 years and older, used a randomized, double-blind, placebo-controlled design, and has been completed.